SARATOGA, Calif., Oct. 11 /PRNewswire/ -- VisionCare Ophthalmic
Technologies, Inc., a developer of advanced visual prosthetic devices for the
treatment of age-related macular degeneration (AMD), announced today three
presentations related to its pivotal trial of the Implantable Miniature
Telescope (IMTTM by Dr. Isaac Lipshitz) are scheduled at the upcoming 109th
Annual Meeting of the American Academy of Ophthalmology (AAO) in Chicago, IL
from October 15 - 18, 2005 at McCormick Place convention center. One-year
safety and efficacy results from the Phase II/III prospective, multicenter AMD
clinical trial are scheduled for presentation as follows:
-- Friday, October 14, 11:28 - 11:36 a.m., Implantable Miniature Telescope
Trial: A Visual Prosthetic Device for End-Stage AMD -- 12-Month Results
from the IMT002 Trial. Paul Sternberg, Jr., MD.
Session: Retina Subspecialty Day, North Hall B1
-- Sunday, October 16, 10:15 - 10:30 a.m., Implantable Miniature
Telescope. Stephen S. Lane, MD.
Session: SPE 12 Vision Rehabilitation Program: Part I Technology and
Techniques for Patients with Macular Degeneration, Room N135
-- Tuesday, October 18, 3:20 - 3:27 p.m., One-Year Phase II/III Results of
a Visual Prosthetic Device for the Treatment of Vision Loss Due to
Macular Degeneration. Henry L. Hudson, MD.
Session: Retina Free Paper Session, Room S406a
VisionCare also announced today that two-year follow-up, specified in the
study protocol for long-term safety surveillance, is now complete. The trial
is evaluating the safety and efficacy of the Company's telescope prosthetic
device in individuals with moderate to profound bilateral central vision
impairment associated with end-stage AMD. The trial enrolled over 200 patients
at 28 leading medical universities and ophthalmic centers across the country.
The telescope prosthetic device is designed to be a permanent solution for
moderate to profound vision loss due to AMD. Smaller than a pea, the telescope
is implanted in one eye in an outpatient surgical procedure. In the implanted
eye, the device renders enlarged central vision images over a wide area of the
retina to improve central vision, while the non-operated eye provides
peripheral vision for mobility and orientation.
About Macular Degeneration
Macular degeneration is a disorder of the central retina, or macula, which
is responsible for detailed vision that controls important functional visual
activities like reading, recognizing faces, and watching television. According
to the National Eye Institute over 1.7 million Americans over age 50 suffer
mild to profound vision loss from advanced AMD, which culminates as end-stage
AMD. Approximately half of the individuals living with advanced AMD are
affected in both eyes.
VisionCare Ophthalmic Technologies, Inc., headquartered in Saratoga, CA is
a privately-held company focused on development, manufacturing, and marketing
of visual prosthetic devices. The Implantable Miniature Telescope was invented
by company founders, Isaac Lipshitz, M.D. and Yossi Gross. Information on
VisionCare can be found at www.visioncareinc.net.
SOURCE VisionCare Ophthalmic Technologies, Inc.